| Literature DB >> 29770344 |
Matthew J Kraeutler1, John W Belk2, Trevor J Carver2, Eric C McCarty2.
Abstract
BACKGROUND: Proper rehabilitation after matrix-associated autologous chondrocyte implantation (MACI) is essential to restore a patient's normal function without overloading the repair site.Entities:
Keywords: articular cartilage; autologous chondrocyte implantation; rehabilitation
Year: 2018 PMID: 29770344 PMCID: PMC5946627 DOI: 10.1177/2325967118770986
Source DB: PubMed Journal: Orthop J Sports Med ISSN: 2325-9671
Figure 1.PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram.
Matrix-Associated Autologous Chondrocyte Implantation Products
| Study | Matrix Scaffold | Manufacturer |
|---|---|---|
| Ebert et al[ | Type I/III collagen membrane (ACI-Maix) | Matricel |
| Wondrasch et al[ | Type I collagen membrane or Hyalograft C | Arthro Kinetics Biotechnology; Fidia Advanced Biopolymers |
Rehabilitation Protocols
| Study | 6 wk | 8 wk | 10/11 wk |
|---|---|---|---|
| Ebert et al[ | X | X | |
| Ebert et al[ | X | X | |
| Ebert et al[ | X | X | |
| Ebert et al[ | X | X | |
| Edwards et al[ | X | X | |
| Wondrasch et al[ | X | X | |
| Wondrasch et al[ | X | X |
Each study randomized patients into 2 of the following 3 rehabilitation protocols: 6-week, 8-week, or 10/11-week return to full weightbearing.
Patient Demographics
| Study | No. of Lesions | Lesion Size, cm2 | Age at Surgery, y | Weight, kg | Height, m | BMI, kg/m2 | Lesion Location, n |
|---|---|---|---|---|---|---|---|
| 6 wk | |||||||
| Ebert et al[ | 18 | 3.2 | 36.4 | 82.3 | 1.76 | 26.2 | LFC: 5 MFC: 13 |
| Wondrasch et al[ | 16 | 5.1 | 28.3 | NR | NR | 24.7 | LFC: 4 MFC: 12 |
| Total | 34 | 4.1 | 32.6 | 82.3 | 1.76 | 25.5 | LFC: 9 MFC: 25 |
| 8 wk | |||||||
| Ebert et al[ | 19 | 2.9 | 36.4 | 79.4 | 1.77 | 25.2 | LFC: 5 MFC: 14 |
| Ebert et al[ | 34 | 3.2 ± 0.5 | 36.6 ± 1.9 | 79.0 ± 1.8 | 1.74 ± 0.02 | 25.6 | LFC: 8 MFC: 26 |
| Total | 53 | 3.1 | 36.5 | 79.1 | 1.75 | 25.5 | LFC: 13 MFC: 40 |
| 10/11 wk | |||||||
| Ebert et al[ | 36 | 3.3 ± 0.5 | 39.7 ± 2.3 | 83.8 ± 2.4 | 1.74 ± 0.02 | 27.6 | LFC: 10 MFC: 26 |
| Wondrasch et al[ | 15 | 4.6 | 38.0 | NR | NR | 24.8 | LFC: 5 MFC: 10 |
| Total | 51 | 3.7 | 39.2 | 83.8 | 1.74 | 26.8 | LFC: 15 MFC: 36 |
Lesion size, age, weight, height, and BMI are all reported as mean ± SD (if available), with “total” reported as weighted mean. Only the nonoverlapping patient samples are included to avoid redundancy. BMI, body mass index; LFC, lateral femoral condyle; MFC, medial femoral condyle; NR, not reported.
Modified Coleman Methodology Score
| Study | Mean Score |
|---|---|
| Ebert et al[ | 68 |
| Ebert et al[ | 84 |
| Ebert et al[ | 87 |
| Ebert et al[ | 84 |
| Edwards et al[ | 68 |
| Wondrasch et al[ | 81 |
| Wondrasch et al[ | 78 |
| Total | 78.6 ± 7.7 |
Treatment Failure
| Study | 6 wk | 8 wk | 10/11 wk | Total |
|---|---|---|---|---|
| Ebert et al[ | 0/18 (0.0) | 2/19 (10.5) | — | 2/37 (5.4) |
| Ebert et al[ | — | 2/34 (5.9) | 3/36 (8.3) | 5/70 (7.1) |
| Wondrasch et al[ | NR | — | NR | NR |
| Total | 0/18 (0.0) | 4/53 (7.5) | 3/36 (8.3) | 7/107 (6.5) |
Failures are reported as number of failures/total number of lesions (%). Only the 3 nonoverlapping patient samples are included to avoid redundancy. NR, not reported.
SF-36 and VAS Scores
| Study | 6 wk | 8 wk | 10/11 wk | |||
|---|---|---|---|---|---|---|
| Preoperative | Postoperative | Preoperative | Postoperative | Preoperative | Postoperative | |
| VAS (frequency) | ||||||
| Ebert et al[ | 6.3 ± 0.6 (n = 18) | 1.6 ± 0.5 (n = 18) | 6.5 ± 0.7 (n = 19) | 1.4 ± 0.5 (n = 19) | — | — |
| Ebert et al[ | — | — | 4.8 ± 0.5 (n = 34) | 2.2 ± 0.5 (n = 34) | 5.4 ± 0.5 (n = 36) | 2.9 ± 0.5 (n = 36) |
| Ebert et al[ | — | — | 4.8 ± 0.5 (n = 31) | 2.2 ± 0.5 (n = 31) | 5.4 ± 0.5 (n = 32) | 3.3 ± 0.3 (n = 32) |
| Total | 6.3 ± 0.6 (n = 18) | 1.6 ± 0.5 (n = 18) | 5.2 ± 0.9 (n = 84) | 2.0 ± 0.6 (n = 84) | 5.4 ± 0.5 (n = 68) | 3.1 ± 0.5 (n = 68) |
| Mean improvement | –4.7 | –3.2 | –2.3 | |||
| Mean follow-up, y | 2.0 | 3.1 | 3.6 | |||
| VAS (severity) | ||||||
| Ebert et al[ | 5.7 ± 0.6 (n = 18) | 1.7 ± 0.4 (n = 18) | 5.3 ± 0.6 (n = 19) | 1.8 ± 0.4 (n = 19) | — | — |
| Ebert et al[ | — | — | 4.6 ± 0.5 (n = 34) | 2.0 ± 0.3 (n = 34) | 4.4 ± 0.5 (n = 36) | 2.5 ± 0.3 (n = 36) |
| Ebert et al[ | — | — | 4.6 ± 0.5 (n = 31) | 2.2 ± 0.4 (n = 31) | 4.4 ± 0.5 (n = 32) | 2.3 ± 0.3 (n = 32) |
| Total | 5.7 ± 0.6 (n = 18) | 1.7 ± 0.4 (n = 18) | 4.8 ± 0.6 (n = 84) | 2.0 ± 0.4 (n = 84) | 4.4 ± 0.5 (n = 68) | 2.4 ± 0.3 (n = 68) |
| Mean improvement | –4.0 | –2.8 | –2.0 | |||
| Mean follow-up, y | 2.0 | 3.1 | 3.6 | |||
| SF-36 PCS | ||||||
| Ebert et al[ | 35.1 ± 1.9 (n = 18) | 49.1 ± 2.5 (n = 18) | 39.6 ± 2.1 (n = 19) | 50.2 ± 2.7 (n = 19) | — | — |
| Ebert et al[ | — | — | 41.5 ± 1.7 (n = 34) | 49.8 ± 1.8 (n = 34) | 37.1 ± 1.7 (n = 36) | 47.0 ± 1.8 (n = 36) |
| Ebert et al[ | — | — | 41.5 ± 3.2 (n = 31) | 48.9 ± 1.7 (n = 31) | 37.1 ± 3.2 (n = 32) | 47.7 ± 2.0 (n = 32) |
| Total | 35.1 ± 1.9 (n = 18) | 49.1 ± 2.5 (n = 18) | 41.1 ± 2.5 (n = 84) | 49.6 ± 2.0 (n = 84) | 37.1 ± 2.5 (n = 68) | 47.3 ± 1.9 (n = 68) |
| Mean improvement | 14.0 | 8.5 | 10.2 | |||
| Mean follow-up, y | 2.0 | 3.1 | 3.6 | |||
| SF-36 MCS | ||||||
| Ebert et al[ | 51.1 ± 2.4 (n = 18) | 54.9 ± 1.7 (n = 18) | 51.5 ± 2.6 (n = 19) | 58.0 ± 1.9 (n = 19) | — | — |
| Ebert et al[ | — | — | 51.2 ± 1.8 (n = 34) | 56.0 ± 1.1 (n = 34) | 52.3 ± 1.8 (n = 36) | 56.1 ± 1.1 (n = 36) |
| Ebert et al[ | — | — | 51.2 ± 3.2 (n = 31) | 55.4 ± 1.4 (n = 31) | 52.3 ± 3.2 (n = 32) | 54.0 ± 1.6 (n = 32) |
| Total | 51.1 ± 2.4 (n = 18) | 54.9 ± 1.7 (n = 18) | 51.3 ± 2.5 (n = 84) | 56.2 ± 1.7 (n = 84) | 52.3 ± 2.5 (n = 68) | 55.1 ± 1.7 (n = 68) |
| Mean improvement | 3.8 | 4.9 | 2.8 | |||
| Mean follow-up, y | 2.0 | 3.1 | 3.6 | |||
Scores are reported as mean ± SD and are taken from the latest postoperative evaluation for each nonoverlapping group of patients, with “total” reported as weighted mean ± composite SD. Significant improvements were found for each outcome in each group (P < .0001). MCS, mental component summary; PCS, physical component summary; SF-36, Short Form Health Survey–36; VAS, visual analog scale.
KOOS Subscores
| Study | 6 wk | 8 wk | 10/11 wk | |||
|---|---|---|---|---|---|---|
| Preoperative | Postoperative | Preoperative | Postoperative | Preoperative | Postoperative | |
| KOOS SR | ||||||
| Ebert et al[ | 26.8 ± 5.8 (n = 18) | 69.0 ± 7.2 (n = 18) | 36.2 ± 6.2 (n = 19) | 69.4 ± 7.7 (n = 19) | — | — |
| Ebert et al[ | — | — | 29.4 ± 4.7 (n = 34) | 61.2 ± 5.8 (n = 34) | 22.8 ± 4.7 (n = 36) | 55.0 ± 5.8 (n = 36) |
| Ebert et al[ | — | — | 29.4 ± 4.7 (n = 31) | 71.9 ± 4.7 (n = 31) | 22.8 ± 4.7 (n = 32) | 62.1 ± 4.2 (n = 32) |
| Wondrasch et al[ | NR | 75.7 ± 19.3 (n = 14) | — | — | NR | 71.5 ± 24.7 (n = 15) |
| Wondrasch et al[ | NR | 67.1 ± 25.1 (n = 14) | — | — | NR | 70.0 ± 25.7 (n = 15) |
| Total | 26.8 ± 5.8 (n = 18) | 70.5 ± 17.9 (n = 46) | 30.9 ± 5.8 (n = 84) | 67.0 ± 7.6 (n = 84) | 22.8 ± 4.7 (n = 68) | 62.1 ± 15.6 (n = 98) |
| Mean improvement | 43.7 | 36.1 | 39.3 | |||
| Mean follow-up, y | 2.9 | 3.1 | 3.6 | |||
| KOOS QOL | ||||||
| Ebert et al[ | 31.7 ± 3.7 (n = 18) | 71.5 ± 5.8 (n = 18) | 35.6 ± 4.0 (n = 19) | 67.3 ± 6.3 (n = 19) | — | — |
| Ebert et al[ | — | — | 37.0 ± 4.1 (n = 34) | 59.6 ± 4.3 (n = 34) | 29.7 ± 4.1 (n = 36) | 58.8 ± 4.3 (n = 36) |
| Ebert et al[ | — | — | 37.0 ± 4.1 (n = 31) | 62.2 ± 4.5 (n = 31) | 29.7 ± 4.1 (n = 32) | 62.9 ± 4.4 (n = 32) |
| Wondrasch et al[ | NR | 63.5 ± 16.0 (n = 14) | — | — | NR | 66.3 ± 21.2 (n = 15) |
| Wondrasch et al[ | NR | 57.3 ± 21.1 (n = 14) | — | — | NR | 61.2 ± 21.4 (n = 15) |
| Total | 31.7 ± 3.7 (n = 18) | 64.7 ± 15.9 (n = 46) | 36.7 ± 4.1 (n = 84) | 62.3 ± 5.7 (n = 84) | 29.7 ± 4.1 (n = 68) | 61.7 ± 12.3 (n = 98) |
| Mean improvement | 33.0 | 25.6 | 32.0 | |||
| Mean follow-up, y | 2.9 | 3.1 | 3.6 | |||
| KOOS pain | ||||||
| Ebert et al[ | 63.2 ± 3.9 (n = 18) | 88.0 ± 3.3 (n = 18) | 66.9 ± 4.2 (n = 19) | 90.2 ± 3.6 (n = 19) | — | — |
| Ebert et al[ | — | — | 69.8 ± 3.2 (n = 34) | 86.1 ± 2.8 (n = 34) | 67.9 ± 3.2 (n = 36) | 82.5 ± 2.8 (n = 36) |
| Ebert et al[ | — | — | 69.8 ± 3.2 (n = 31) | 85.5 ± 3.1 (n = 31) | 67.9 ± 3.2 (n = 32) | 86.0 ± 2.3 (n = 32) |
| Wondrasch et al[ | NR | 82.7 ± 12.9 (n = 14) | — | — | NR | 84.5 ± 17.4 (n = 15) |
| Wondrasch et al[ | NR | 83.1 ± 15.3 (n = 14) | — | — | NR | 86.0 ± 12.7 (n = 15) |
| Total | 63.2 ± 3.9 (n = 18) | 84.9 ± 11.2 (n = 46) | 69.1 ± 3.6 (n = 84) | 86.8 ± 3.6 (n = 84) | 67.9 ± 3.2 (n = 68) | 84.5 ± 8.6 (n = 98) |
| Mean improvement | 21.7 | 17.7 | 16.6 | |||
| Mean follow-up, y | 2.9 | 3.1 | 3.6 | |||
| KOOS symptoms | ||||||
| Ebert et al[ | 64.0 ± 4.3 (n = 18) | 86.1 ± 2.5 (n = 18) | 73.1 ± 4.6 (n = 19) | 88.8 ± 2.6 (n = 19) | — | — |
| Ebert et al[ | — | — | 74.5 ± 3.2 (n = 34) | 88.0 ± 2.6 (n = 34) | 68.6 ± 3.2 (n = 36) | 82.9 ± 2.6 (n = 36) |
| Ebert et al[ | — | — | 74.5 ± 3.2 (n = 31) | 86.4 ± 3.1 (n = 31) | 68.6 ± 3.2 (n = 32) | 83.5 ± 4.2 (n = 32) |
| Wondrasch et al[ | NR | 66.9 ± 4.5 (n = 14) | — | — | NR | 62.8 ± 9.8 (n = 15) |
| Wondrasch et al[ | NR | 63.5 ± 15.8 (n = 14) | — | — | NR | 58.7 ± 13.1 (n = 15) |
| Total | 64.0 ± 4.3 (n = 18) | 73.4 ± 13.7 (n = 46) | 74.2 ± 3.6 (n = 84) | 87.6 ± 2.9 (n = 84) | 68.6 ± 3.2 (n = 68) | 76.3 ± 12.5 (n = 98) |
| Mean improvement | 9.4 | 13.4 | 7.7 | |||
| Mean follow-up, y | 2.9 | 3.1 | 3.6 | |||
| KOOS ADL | ||||||
| Ebert et al[ | 73.8 ± 3.9 (n = 18) | 92.3 ± 2.8 (n = 18) | 80.6 ± 4.2 (n = 19) | 95.4 ± 3.0 (n = 19) | — | — |
| Ebert et al[ | — | — | 81.9 ± 3.2 (n = 34) | 92.8 ± 2.4 (n = 34) | 76.9 ± 3.2 (n = 36) | 90.3 ± 2.4 (n = 36) |
| Ebert et al[ | — | — | 81.9 ± 3.2 (n = 31) | 92.3 ± 2.2 (n = 31) | 76.9 ± 3.2 (n = 32) | 93.2 ± 1.8 (n = 32) |
| Wondrasch et al[ | NR | 88.2 ± 10.6 (n = 14) | — | — | NR | 87.7 ± 16.1 (n = 15) |
| Wondrasch et al[ | NR | 86.3 ± 15.8 (n = 14) | — | — | NR | 88.7 ± 12.6 (n = 15) |
| Total | 73.8 ± 3.9 (n = 18) | 89.2 ± 10.7 (n = 46) | 81.6 ± 3.4 (n = 84) | 93.2 ± 2.7 (n = 84) | 76.9 ± 3.2 (n = 68) | 90.6 ± 8.2 (n = 98) |
| Mean improvement | 15.4 | 11.6 | 13.7 | |||
| Mean follow-up, y | 2.9 | 3.1 | 3.6 | |||
Subscores are reported as mean ± SD, with “total” reported as weighted mean ± composite SD. Significant improvements were found for each outcome in each group (P < .001). ADL, activities of daily living; KOOS, Knee injury and Osteoarthritis Outcome Score; NR, not reported; QOL, quality of life; SR, sports and recreation.
Functional Test Results
| Study | 6 wk | 8 wk | 10/11 wk | |||
|---|---|---|---|---|---|---|
| Preoperative | Postoperative | Preoperative | Postoperative | Preoperative | Postoperative | |
| 6-min walk test, m | ||||||
| Ebert et al[ | NR | 656.0 ± 22.0 (n = 18) | NR | 664.0 ± 24.0 (n = 19) | — | — |
| Ebert et al[ | — | — | 556.8 ± 20.5 (n = 34) | 661.5 ± 20.1 (n = 34) | 528.2 ± 20.5 (n = 36) | 580.7 ± 20.1 (n = 36) |
| Ebert et al[ | — | — | 556.8 ± 20.5 (n = 31) | 630.6 ± 20.5 (n = 31) | 528.2 ± 20.5 (n = 32) | 616.1 ± 15.1 (n = 32) |
| Total | — | 656.0 ± 22.0 (n = 18) | 556.8 ± 20.3 (n = 65) | 650.7 ± 26.0 (n = 84) | 528.2 ± 20.3 (n = 68) | 597.4 ± 25.2 (n = 68) |
| Mean improvement | — | 93.9 | 69.2 | |||
| Mean follow-up, y | 2.0 | 3.1 | 3.4 | |||
| Maximum knee flexion, deg | ||||||
| Ebert et al[ | NR | 143.6 ± 1.8 (n = 18) | NR | 144.8 ± 2.0 (n = 19) | — | — |
| Ebert et al[ | — | — | 135.4 ± 2.3 (n = 34) | 143.6 ± 1.6 (n = 34) | 128.5 ± 2.4 (n = 36) | 139.5 ± 1.6 (n = 36) |
| Ebert et al[ | — | — | 135.4 ± 2.2 (n = 31) | 139.8 ± 1.5 (n = 31) | 128.5 ± 2.4 (n = 32) | 138.7 ± 1.3 (n = 32) |
| Total | — | 143.6 ± 1.8 (n = 18) | 135.4 ± 2.2 (n = 65) | 142.5 ± 2.7 (n = 84) | 128.5 ± 2.4 (n = 68) | 139.1 ± 1.5 (n = 68) |
| Mean improvement | — | 7.1 | 10.6 | |||
| Mean follow-up, y | 2.0 | 3.1 | 3.4 | |||
| Maximum knee extension, deg | ||||||
| Ebert et al[ | NR | –1.8 ± 0.4 (n = 18) | NR | –2.0 ± 0.4 (n = 19) | — | — |
| Ebert et al[ | — | — | 0.4 ± 0.4 (n = 34) | –0.7 ± 0.2 (n = 34) | 0.7 ± 0.4 (n = 36) | 0.1 ± 0.2 (n = 36) |
| Ebert et al[ | — | — | 0.4 ± 0.4 (n = 31) | –0.6 ± 0.3 (n = 31) | 0.7 ± 0.4 (n = 32) | –0.3 ± 0.5 (n = 32) |
| Total | — | –1.8 ± 0.4 (n = 18) | 0.4 ± 0.4 (n = 65) | –1.0 ± 0.6 (n = 84) | 0.7 ± 0.4 (n = 68) | –0.1 ± 0.4 (n = 68) |
| Mean improvement | — | –1.4 | –0.8 | |||
| Mean follow-up, y | 2.0 | 3.1 | 3.4 | |||
Results are reported as mean ± SD, with “total” reported as weighted mean ± composite SD. Significant improvements were found for each outcome in the 8-week and 10/11-week groups (P < .0001). NR, not reported.